In vivo and in silico studies on single versus multiple transplants for multiple myeloma

Cancer Science

Volumn 98, Issue 5, 2007, Pages 734-739

  Dingli, David ^a,b   Pacheco, Jorge M ^b,c   Dispenzieri, Angela ^a   Hayman, Suzanne R ^a   Kumar, Shaji K ^a   Lacy, Martha Q ^a   Gastineau, Dennis A ^a   Gertz, Morie A ^a  

^a Mayo Clinic   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; M PROTEIN;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROBABILITY; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; COMPUTER SIMULATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 34147099990     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00450.x     Document Type: Article

References (31)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-7.
2. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-502.
3. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
4. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-6.
5. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
6. Moreau P, Facon T, Attal M et al. Comparison of 200 mg/m (2) melphalan and 8 Gy total body irradiation plus 140 mg/m (2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731-5.
7. Barlogie B, Kyle RA, Anderson KC et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-36.
8. Cunningham D, Powles R, Malpas J et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. Br J Haematol 1998; 102: 495-502.
9. Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771-9.
10. Dingli D, Nowakowski GS, Dispenzieri A et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384-8.
11. Sullivan PW, Salmon SE. Kinetics of tumor growth and regression in IgG multiple myeloma. J Clin Invest 1972; 51: 1697-708.
12. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-9.
13. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988; 48: 7067-71.
14. Bajzer Z. Gompertzian growth as a self-similar and allometric process. Growth Dev Aging 1999; 63: 3-11.
15. Kozusko F, Bajzer Z. Combining Gompertzian growth and cell population dynamics. Math Biosci 2003; 185: 153-67.
16. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT, European Group for Blood Marrow Transplant. Br J Haematol 1998; 102: 1115-23.
17. Salmon SE, Durie BGM. Cellular kinetics in multiple myeloma. Arch Intern Med 1975; 135: 131-8.
18. Buffaloe GW, Heineken FG. Plasma volume nomograms for use in therapeutic plasma exchange. Transfusion 1983; 23: 355-7.
19. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333-8.
20. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: What have we learned? Blood 1996; 88: 838-47.
21. Barlogie B, Jagannath S, Naucke S et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998; 21: 1101-7.
22. Cunningham D, Paz-Ares L, Milan S et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-63.
23. Gertz MA, Lacy MQ, Inwards DJ et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000; 26: 45-50.
24. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-43.
25. Dingli D, Nowakowski GS, Dispenzieri A et al. Flow cytometric detection of circulating myeloma cells before transplant in patients with multiple myeloma: A simple risk stratification system. Blood 2006; 107: 3384-8.
26. San Miguel JF, Garcia-Sanz R, Gonzalez M et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448-55.
27. Rajkumar SV, Fonseca R, Dewald GW et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999; 113: 73-7.
28. Shaughnessy JD Jr. Global gene expression profiling in the study of multiple myeloma. Int J Hematol 2003; 77: 213-25.
29. Mitsiades CS, Mitsiades N, Treon SP, Anderson KC. Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Semin Oncol 2003; 30: 156-60.
30. Tabrizi MA, Tseng C-M, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discovery Today 2006; 11: 81-8.
31. Pacheco JM. Probability Calculator. 2007. Available from URL: http://www.ciul.ul.pt/~pacheco/MM/calc.php